



Pfizer Inc.
235 East 42nd St.
New York, NY 10017

August 20, 2021

Subject: Norpace® CR 100 mg and 150 mg: timeline for shortage resolution

Dear Healthcare Provider,

The purpose of this letter is to inform you that the supply shortage of Norpace CR 100 mg and Norpace CR 150 mg (disopyramide phosphate extended-release capsules) is expected to be resolved by **January 2022**. There is no impact on Norpace IR (disopyramide phosphate immediate release) capsules.

Product	Current Status	Date Shortage Occurred	Date when shortage is expected to be resolved
Norpace CR 150 mg	Out of stock	August 2020	January 2022
Norpace CR 100 mg	Out of stock	October 2020	January 2022

Pfizer recognizes the importance of Norpace CR for your patients.

Healthcare professionals should use their clinical expertise to determine an alternative treatment option for their patients in the interim. Pfizer cannot make recommendations regarding alternative treatments.

Norpace CR is indicated for the treatment of documented ventricular arrhythmias. For additional medical questions on Norpace CR, please contact Pfizer Medical Information 1-800-438-1985. Please see full prescribing information, including Boxed Warnings, available at: <http://labeling.pfizer.com/ShowLabeling.aspx?id=634>

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,

Sveta Ferri
Sveta Ferri, PharmD
US Medical Affairs
Pfizer Inc.